Clinical trial

Spiriva® Assessment of FEV1 (SAFE)

NCT00277264

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-01-01

PhasePHASE3

Study timeline

Study start (unknown)2002-01-01Date precision: month

Registry last updated2013-11-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

Tiotropium (Spiriva®)DRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

TorontoOntario, Canada10 MontrealQuebec, Canada7 LondonOntario, Canada5 HamiltonOntario, Canada5 OttawaOntario, Canada4 SaskatoonSaskatchewan, Canada4 VancouverBritish Columbia, Canada3 CalgaryAlberta, Canada3 EdmontonAlberta, Canada1 QuébecQuebec, Canada1 WinnipegManitoba, Canada1 SherbrookeQuebec, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00277264 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.